June 1st 2024
Brentuximab vedotin led to unprecedented progression-free survival for patients with classical Hodgkin lymphoma.
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Tisagenlecleucel Granted FDA Priority Review for Relapsed/Refractory Follicular Lymphoma
October 28th 2021Patients with relapsed or refractory follicular lymphoma who have received 2 prior lines of therapy appear to benefit from treatment with tisagenlecleucel, which was granted a priority review by the FDA.
Expert Commentary on the Product Profile of Umbralisib for Lymphoma
October 17th 2021In an interview with ONCOLOGY®, Douglas Braun, CSP, PharmD, RPh, offers a comprehensive review of real-world treatment considerations of umbralisib as therapy for patients with previously treated follicular and marginal zone lymphoma.
FDA Grants Accelerated Approval to Zanubrutinib for Relapsed/Refractory MZL
September 15th 2021Based on response data from the phase 2 MAGNOLIA trial, the FDA has granted accelerated approval to the Bruton tyrosine kinase inhibitor zanubrutinib to treat patients with relapsed/refractory marginal zone lymphoma.